Mgc Pharmaceuticals Share Discussion Threads

[goforgold1] 10/2/2022 14:42

Ha Ha you clutching at straws lol 2.7 billion shares

[sloppyjoe2] 10/2/2022 14:41

I have no idea.

[heatseek77] 10/2/2022 14:39

Little bounce back markets awful at moment

[heatseek77] 10/2/2022 14:38

Little bounce back

[heatseek77] 10/2/2022 14:37

Hoder you certainly write like you are the other one

[hoder] 10/2/2022 14:12

H77

Please stop it; I am not the great one. I am merely an average Joe who got ponzied like all of you.

Claiming me being the Great one, should not be used as a deflection, all shareholders are underwater. I cut big losses here.

But let us keep an eye on the ball, is the share price depreciating?

Do you prefer I lose money? I am up to my neck in this sack of Tumeric; please excuse my pun.

[heatseek77] 10/2/2022 13:49

Hoder on the other thread is clearly another one of Bad Robots aliases then 🤷

[heatseek77] 10/2/2022 13:43

goldilocks1 graft polymer who cares, different company

[hoder] 10/2/2022 13:40

My wealth was disappearing rapidly here; I bit the bullet. How the hell, will I be able to tell my three-year-old illegitimate ginger son he will not go to Uni in 15 years, he was born while I was in prison for 5 years. I have gambled all the family silverware on a Tumeric get rich quick scam. Pierre was promoting a 1p rise per month.

Perhaps BR could let me stay in his transit/caravan in Snowdonia rather than facing the toddler.

[goforgold1] 10/2/2022 13:14

Name: MGC Pharmaceuticals Limited
Ticker: MXC
Exchange: ASX
Founded: 2014
Industry: Pharmaceuticals
Sector: Pharmaceuticals & Biotech
Implied Market Cap: AU$83.716m
Shares outstanding: 2.70b
Website:

[goforgold1] 10/2/2022 12:59

DOES THIS SOUND FAMILER LOL ROBY NEW COMPANY AND ANOTHER 5 MILLION IN BANK

Business Update

Graft Polymer (UK) Plc (LSE: GPL), a business focused on the development of polymer modification, bio/food supplements and drug delivery systems, is pleased to provide the following update on three key areas of the business: Commercial trials with customers are progressing well and leading to order requests. patents and the development of Graft Polymer's layered IP strategy continue to be strengthened; and operational progress against the wider product development has been expertly executed.

Ongoing commercial trials

In 2021, Graft Polymer was involved in successful and exciting trials with leading companies across Europe and internationally. Presently, the trials are at various stages, with some having already resulted in commercial order requests. It is expected that the number of orders will increase during 2022-2023, some leading to further partnerships and others moving into the next stage of the trial.

Graft Polymer's innovative technology is proving to be successful across a wide range of the products in the Company's portfolio. The markets in which Graft Polymer operates are significant in size, and rapidly growing. Research and development remain core to its strategy. The successful trials, and positive validation tests, include ten separate polymers from our GRAFTBOND and GRAFTALEN product lines.

Patent Update

Graft Polymer is also pleased to announce that patent No. P-2021106347 has had its application accepted by the Federal Service for Intellectual Property in Russia and the Slovenian Intellectual Property Office. The patent application, which relates to core technologies included in Graft Polymer's proprietary drug delivery system, focuses on smart nanostructured materials to deliver drugs to target sites with the aim of reducing dosage frequency and mitigate the side effects experienced with traditional therapies.

Furthermore, progress has been made with patent application P-202100024 and has been awarded. The patent covers the super-saturable self-nano emulsifying drug delivery system (SNEDDS) for poorly water-soluble pharmaceutical compositions and method of its preparation. Graft Polymer has five patent applications accepted that are now included in the database of relevant authorities in Europe and Russia and are awaiting award.

Strategy Update

Building from its successful IPO on the 6 January 2022, Graft Polymer has made strong strategic progress and has the following aims:

1) Reduction in in-house manufacturing cost of porous polymer carriers by enhancing Graft Polymer drying capacities: This will enable Graft Polymer to expand the addressable market and to further increase the sales volume;

2) Lower manufacturing cost of Graft Polymer's block copolymers and reactive masterbatches: Graftapor and Graftakit are the Graft Polymer exclusive high value-added products without any current competition in the market;

3) Open a "Hot Ozone/Plasma Modification" module: It will enable Graft Polymer to produce;
a. Grafted Fluoropolymers (PVDF, PTFE, ETFE, PFA etc); and
b. Polymeric Ozonides based on terpenoids and poly-alpha-olefins, products used as initiators in polymerization reactions and pharma multi applications.

Victor Bolduev, Chief Executive Officer of Graft Polymer, commented: "We are very pleased to progress the status of patent P-2021106347 and look forward to adding more patents to our growing IP portfolio. Our technology supporting our Drug Delivery Systems is highly sophisticated and allows us to operate in the important global DDS market which was valued at over USD$25 billion in 2019 and is projected to reach USD$45 billion by 2027.

"We are excited to see Graft Polymers expansion, and the execution of our business strategy being implemented during 2022. "

[goforgold1] 10/2/2022 12:58

DOES THIS SOUND Familiar. lol His new company come to market raised another 5 million FOOD COMPANY NOW LOL


Business Update

Graft Polymer (UK) Plc (LSE: GPL), a business focused on the development of polymer modification, bio/food supplements and drug delivery systems, is pleased to provide the following update on three key areas of the business: Commercial trials with customers are progressing well and leading to order requests. patents and the development of Graft Polymer's layered IP strategy continue to be strengthened; and operational progress against the wider product development has been expertly executed.

Ongoing commercial trials

In 2021, Graft Polymer was involved in successful and exciting trials with leading companies across Europe and internationally. Presently, the trials are at various stages, with some having already resulted in commercial order requests. It is expected that the number of orders will increase during 2022-2023, some leading to further partnerships and others moving into the next stage of the trial.

Graft Polymer's innovative technology is proving to be successful across a wide range of the products in the Company's portfolio. The markets in which Graft Polymer operates are significant in size, and rapidly growing. Research and development remain core to its strategy. The successful trials, and positive validation tests, include ten separate polymers from our GRAFTBOND and GRAFTALEN product lines.

Patent Update

Graft Polymer is also pleased to announce that patent No. P-2021106347 has had its application accepted by the Federal Service for Intellectual Property in Russia and the Slovenian Intellectual Property Office. The patent application, which relates to core technologies included in Graft Polymer's proprietary drug delivery system, focuses on smart nanostructured materials to deliver drugs to target sites with the aim of reducing dosage frequency and mitigate the side effects experienced with traditional therapies.

Furthermore, progress has been made with patent application P-202100024 and has been awarded. The patent covers the super-saturable self-nano emulsifying drug delivery system (SNEDDS) for poorly water-soluble pharmaceutical compositions and method of its preparation. Graft Polymer has five patent applications accepted that are now included in the database of relevant authorities in Europe and Russia and are awaiting award.

Strategy Update

Building from its successful IPO on the 6 January 2022, Graft Polymer has made strong strategic progress and has the following aims:

1) Reduction in in-house manufacturing cost of porous polymer carriers by enhancing Graft Polymer drying capacities: This will enable Graft Polymer to expand the addressable market and to further increase the sales volume;

2) Lower manufacturing cost of Graft Polymer's block copolymers and reactive masterbatches: Graftapor and Graftakit are the Graft Polymer exclusive high value-added products without any current competition in the market;

3) Open a "Hot Ozone/Plasma Modification" module: It will enable Graft Polymer to produce;
a. Grafted Fluoropolymers (PVDF, PTFE, ETFE, PFA etc); and
b. Polymeric Ozonides based on terpenoids and poly-alpha-olefins, products used as initiators in polymerization reactions and pharma multi applications.

Victor Bolduev, Chief Executive Officer of Graft Polymer, commented: "We are very pleased to progress the status of patent P-2021106347 and look forward to adding more patents to our growing IP portfolio. Our technology supporting our Drug Delivery Systems is highly sophisticated and allows us to operate in the important global DDS market which was valued at over USD$25 billion in 2019 and is projected to reach USD$45 billion by 2027.

"We are excited to see Graft Polymers expansion, and the execution of our business strategy being implemented during 2022. "

[goforgold1] 10/2/2022 12:51

1p coming soon and thats still over priced.

WHAT HAPPENED TO THE 25 MILLON DEAL LOL . GO LOOK WHO OWNS AND RUNS THE COMPANY ONE OF HIS GOOD FRIENDS I BET THEY NEVER EVEN TRANSFERED MONEY OVER LOL. ALL PAPER TRAILS.

25 Millon deal and only had if they really have £750,000 so that means another 24 million to come ha ha more chance you wining lotto than seeing all that money

[goforgold1] 10/2/2022 12:50

Don't buy this DOG its a Con 2.7 billion shares and counting lol . another 9 million more coming soon as well. THIS ROBY NEEDS INVESTIGATING COME ON LETS GET A EMAIL TOGETHER SEND LSE

[beltd] 10/2/2022 12:49

They'll be revving up the presses again soon buddy

[goforgold1] 10/2/2022 12:13

2.7bn + 200m =

[goforgold1] 10/2/2022 12:11

for being a re seller of vapers lol . You could not make this up lol.

Bel is that total shares out there now wow. In total what about 9 million coming for Turner Pope

[beltd] 10/2/2022 12:09

2.7bn + 200m =

[goforgold1] 10/2/2022 11:44

What's the price lol all time low

[heatseek77] 10/2/2022 11:24

Sloppyjoe2 sounds a sad state of affairs all around really ☹️

He's not goldilocks1 is he? 🤔

[sloppyjoe2] 10/2/2022 11:21

Heatseek - Dean Haigh is a serial online stalker. His primary target is Festario, who he has been stalking for 6 years or more. There are several complaints to the police outstanding against him. He is a sad, pathetic loser, lives on benefits in a succession of seedy bedsits. His wife left him because of his multiple inadequacies. He really is a pathetic sadsack.

[heatseek77] 10/2/2022 11:14

And why the beef??

[heatseek77] 10/2/2022 11:14

Cheers Sam, Sloppy who is Dean Haigh??